Magnesium Sulfate; Postoperative Nausea and Vomiting; Laparoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
Postoperative nausea and vomiting (PONV) is commonly accompanied in patients undergoing surgery under general anesthesia. The patients undergoing laparoscopic gynecologic surgery have multiple risk factors for developing PONV such as female gender, nonsmoker, postoperative opioids, and laparoscopic surgery. Thus, it is important to prevent PONV in these patients.

Detailed Description
-----------------
Magnesium is a N-methyl-D-aspartate (NMDA) antagonist that is known to be effective in reducing opioid consumption and controlling postoperative pain. This opioid reducing effect can be associated with reduction of the incidence of PONV. However, the effect of magnesium on preventing PONV have not been investigated before. Thus, the investigators hypothesized that intraoperative infusion of magnesium will be effective in preventing PONV in patients undergoing laparoscopic gynecologic surgery.

Official Title
-----------------
The Effect of Intravenous Magnesium Sulfate on Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynecologic Surgery

Conditions
-----------------
Gynecologic Disease

Intervention / Treatment
-----------------
* Drug: Mg (magnesium sulfate)
* Drug: Control (saline)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gynecologic disease Female patients undergoing laparoscopic gynecologic surgery and receiving postoperative fentanyl based intravenous patient controlled analgesia (PCA), aged 20-65 years. Exclusion Criteria: impaired renal or hepatic function (Glutamic Oxalacetate Transaminase [GOT]/Glutamic Pyruvate Transaminase [GPT]>50, estimated glomerular filtration rate [eGFR]<60) atrioventricular block, myopathies, diabetes, treated with calcium channel blockers History of receiving antiemetics within 1 day before surgery History of receiving opioids or non-steroidal anti-inflammatory drugs within 1 week of surgery drugs or alcohol abuse patients treated with isoniazid, chlorpromazine, or digoxin patients who cannot communicated with others or with cognitive dysfunction patients who cannot read informed consent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mg group<br>20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation. | Drug: Mg (magnesium sulfate)<br>* 20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.<br>* Other names: Masi;|
| Placebo Comparator: Control group<br>Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation. | Drug: Control (saline)<br>* The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.<br>* Other names: Normal saline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of PONV | The incidence of PONV will be measured up to postoperative 2 days. | up to postoperative 2 days |